Alpha-glucosidase inhibitors

ApprovedSmall molecule

Alpha-glucosidase inhibitors is one of 140 small molecule programs targeting Acute Pancreatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

139

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute PancreatitisActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Pancreatic CancerActive, not recruiting

Heart FailureActive, not recruiting

Type 2 DiabetesActive, not recruiting

Acute PancreatitisPreclinical

Active, not recruiting

Type 2 Diabetes MellitusApproved

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Heart FailurePreclinical

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Alpha-glucosidase inhibitors

Sanofi

Approved

1 2

Gemzar

GGynecologic Oncology Group

MS Contin

1 4

Medrol

Pfizer

Preclinical

1 5

Byetta

AstraZeneca

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Chemotherapy Agents

Takeda

Preclinical

1 9

Secretin-Ferring

Ferring

Preclinical

1 10

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

Incretin-based Drugs and Pancreatic Cancer

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02475499·886,172 enrolled

Type 2 Diabetes Mellitus1 trial

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Completed· Sanofi logo

Sanofi·Phase 4·NCT02954692·112 enrolled

Type 2 Diabetes1 trial

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT02730377·1,991 enrolled

Heart Failure1 trial

Incretin-based Drugs and the Risk of Heart Failure

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02456428·1,499,650 enrolled

Acute Pancreatitis1 trial

Incretin-based Drugs and Acute Pancreatitis

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02476760·1,417,914 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Alpha-glucosidase inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alpha-glucosidase inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alpha-glucosidase inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Alpha-glucosidase inhibitors

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatic Cancer1 trial

Type 2 Diabetes Mellitus1 trial

Type 2 Diabetes1 trial

Heart Failure1 trial

Acute Pancreatitis1 trial

References

Drug Info

Quick Facts

Related News